Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biosimilar Characterization R&D Facility Opens in Austria

Published: Wednesday, October 23, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
University of Salzburg, Sandoz and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development, production, QA/QC.

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and  scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.
 
The new facility, co-funded by the Austrian Federal Ministry of Economy, Family and Youth, as well as the County of Salzburg through the Christian Doppler Society, was established to develop and transfer to practice novel and more efficient methods to characterize the active ingredients in protein-based medicines. Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific are collaborating in these efforts.
 
“The more physical, chemical and biological data we can obtain for protein-based drugs, the more certain we can be that they will produce the desired effects and will not produce unexpected adverse effects,” explains Prof. Christian Huber, head of the new Christian Doppler lab. “Here, we are joining expertise in protein production and characterization, structural biology and synthetic chemistry at the University of Salzburg to develop innovative characterization tools to determine the efficacy and safety of protein-based medicines.”
 
“As the leader in protein characterization technology, we are confident that we will make a significant technical contribution to the detailed analysis of biosimilars and their quality control,” observes Dr. Alain Guiller, vice president of global sales, life science mass spectrometry (LC-MS) at Thermo Fisher Scientific. “This is a rapidly-developing field, and this close cooperation with the University of Salzburg and Sandoz will increase our understanding and help us to serve the emerging needs of the pharmaceutical industry.
 
Thermo Fisher’s participation will focus on providing expertise for applying Orbitrap-based LC-MS technology, nano-UHPLC (ultra high-perfomance liquid chromatography) systems and columns, and software to future workflows for protein-based drug characterization and quality control.
 
“For us, the collaboration constitutes an important means to gain access to very recent technologies for industrial application, in order to make our production safer and more efficient,” adds Dr. Andreas Premstaller, head  of Sandoz’ Schaftenau production site.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Strengthens Bioprocessing Offering with Advanced Scientifics Acquisition
Thermo Fisher Scientific has acquired Advanced Scientifics, Inc., a global provider of single-use technologies for customized bioprocessing solutions, for $300 million in cash.
Friday, February 06, 2015
Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo Fisher, BioAnalytix Collaborate
Collaboration to develop advanced biopharmaceutical analysis workflows.
Thursday, June 12, 2014
Thermo Reports 22% Revenue Rise in Q1 2014
Results include the addition of Life Technologies as of February 4, 2014, and exclude the previously announced related divestitures as of March 22, 2014.
Wednesday, April 23, 2014
Thermo Completes Life Tech Acquisition
The completion of the transaction follows the receipt of all required regulatory approvals.
Tuesday, February 04, 2014
Thermo Fisher Scientific Opens Its First Dry Powder Media Facility in APAC Region
Singapore facility delivers manufacturing redundancy and increases supply assurance for global biologic drug discovery and production.
Tuesday, August 06, 2013
Thermo Fisher Scientific Expands Shanghai Production Capacity
First global company to locally produce cell culture consumable products in China for China.
Friday, January 21, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!